Eliana Merle
Stock Analyst at UBS
(3.35)
# 1,055
Out of 5,006 analysts
98
Total ratings
49.32%
Success rate
4.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Maintains: Buy | $72 → $82 | $53.83 | +52.33% | 4 | Sep 12, 2025 | |
| GOSS Gossamer Bio | Upgrades: Buy | $1.25 → $9 | $2.50 | +260.00% | 3 | Sep 10, 2025 | |
| ALT Altimmune | Maintains: Buy | $26 → $24 | $3.90 | +516.17% | 2 | Aug 13, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $8 → $9 | $28.53 | -68.45% | 4 | Aug 12, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $458 → $523 | $435.87 | +19.99% | 5 | Aug 12, 2025 | |
| ANAB AnaptysBio | Maintains: Neutral | $18 → $20 | $29.70 | -32.66% | 5 | Aug 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $306 → $307 | $208.81 | +47.02% | 2 | Aug 8, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $113 → $114 | $54.89 | +107.69% | 3 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $403 → $550 | $455.57 | +20.73% | 3 | Aug 1, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $45 → $12 | $23.08 | -48.01% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $2.93 | +173.04% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $5.5 | $5.41 | +1.66% | 3 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $9.29 | +126.05% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $56.32 | +24.29% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $70 | $27.11 | +158.25% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $24.70 | +78.14% | 8 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $38 | $14.83 | +156.24% | 3 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $109 | $45.93 | +137.32% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $1.59 | +38.80% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $46.33 | +53.25% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $13.46 | +108.10% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $7.15 | +67.83% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $3 | $5.62 | -46.62% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $105.30 | +24.41% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $14.12 | -64.59% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $8.08 | +122.77% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $53.21 | -21.07% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $7.34 | +199.73% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $10.40 | +352.14% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $8.11 | +97.41% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $34.79 | +285.17% | 3 | Aug 19, 2020 |
BridgeBio Pharma
Sep 12, 2025
Maintains: Buy
Price Target: $72 → $82
Current: $53.83
Upside: +52.33%
Gossamer Bio
Sep 10, 2025
Upgrades: Buy
Price Target: $1.25 → $9
Current: $2.50
Upside: +260.00%
Altimmune
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $3.90
Upside: +516.17%
RAPT Therapeutics
Aug 12, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $28.53
Upside: -68.45%
Madrigal Pharmaceuticals
Aug 12, 2025
Maintains: Buy
Price Target: $458 → $523
Current: $435.87
Upside: +19.99%
AnaptysBio
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $29.70
Upside: -32.66%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $306 → $307
Current: $208.81
Upside: +47.02%
BioMarin Pharmaceutical
Aug 5, 2025
Maintains: Buy
Price Target: $113 → $114
Current: $54.89
Upside: +107.69%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $403 → $550
Current: $455.57
Upside: +20.73%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $23.08
Upside: -48.01%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.93
Upside: +173.04%
Jun 26, 2025
Downgrades: Neutral
Price Target: $12 → $5.5
Current: $5.41
Upside: +1.66%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $9.29
Upside: +126.05%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $56.32
Upside: +24.29%
May 2, 2025
Maintains: Buy
Price Target: $78 → $70
Current: $27.11
Upside: +158.25%
Apr 29, 2025
Initiates: Overweight
Price Target: $44
Current: $24.70
Upside: +78.14%
Jan 31, 2025
Maintains: Buy
Price Target: $25 → $38
Current: $14.83
Upside: +156.24%
Jan 31, 2025
Maintains: Buy
Price Target: $42 → $109
Current: $45.93
Upside: +137.32%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.59
Upside: +38.80%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $46.33
Upside: +53.25%
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $13.46
Upside: +108.10%
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $7.15
Upside: +67.83%
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $5.62
Upside: -46.62%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $105.30
Upside: +24.41%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $14.12
Upside: -64.59%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $8.08
Upside: +122.77%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $53.21
Upside: -21.07%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $7.34
Upside: +199.73%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $10.40
Upside: +352.14%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $8.11
Upside: +97.41%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $34.79
Upside: +285.17%